Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715709 | 0.86 | PTGS2 (0.44) | PTGS2PTGS1POLBERN1KIF11 | |
| SCHEMBL5715411 | 0.85 | PTGS2 (0.45) | PTGS2PTGS1POLBTGFBR1 | |
| SCHEMBL5715568 | 0.77 | PTGS2 (0.69) | PTGS2POLBERN1SMN1; SMN2 | |
| SCHEMBL27705512 | 0.75 | SLC6A9 (0.52) | SMN1; SMN2 | |
| SCHEMBL31510237 | 0.75 | POLB (0.64) | PTGS2PTGS1POLBSMN1; SMN2LRRK2 | |
| SCHEMBL6114325 | 0.75 | POLB (0.64) | PTGS2PTGS1POLBSMN1; SMN2LRRK2 | |
| SCHEMBL5715461 | 0.73 | PTGS2 (0.49) | PTGS2POLBERN1KIF11 | |
| SCHEMBL10300269 | 0.73 | PTGS2 (0.62) | PTGS2PTGS1KIF11 | |
| SCHEMBL7677302 | 0.73 | PTGS2 (0.62) | PTGS2PTGS1KIF11 | |
| SCHEMBL9034923 | 0.72 | PTGS2 (0.55) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434762-B1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2006-12-20 | — | — | EP | claimed |
| US-6583321-B1 | Nonsteroid, antiinflammatory; side effect reduction | CHEIL JEDANG CORPORATION (KR) | 2003-06-24 | — | — | US | claimed |
| US-20030105095-A1 | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-05 | — | — | US | claimed |
| EP-1434762-B1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2006-12-20 | — | — | EP | disclosed |
| EP-1434762-A4 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1434762-A1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-07-07 | — | — | EP | disclosed |
| US-6583321-B1 | Nonsteroid, antiinflammatory; side effect reduction | CHEIL JEDANG CORPORATION (KR) | 2003-06-24 | — | — | US | disclosed |
| US-20030105095-A1 | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-05 | — | — | US | disclosed |
| WO-2003031398-A1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105095-A1 | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885POLB 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.